N/A
N=13
(KIWI) Speeding up a Slow Protein for Muscle Mass With Hay Kiwifruit
Metabolism · Protein
Bottom Line
View on ClinicalTrials.gov: NCT04356573 ↗Enrolled (actual)
13
Serious AEs
0.0%
Results posted
Nov 2021
Primary outcome: Primary: Whole Body Net Balance Measured by Gas Chromatography-Mass Spectrometry (GC-MS) — 14.58; 14.55 g protein per 300 mins
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Green Hayward Kiwifruit first, then Gold Kiwifruit (Dietary_supplement); Gold Kiwifruit First, then Green Hayward Kiwifruit (Dietary_supplement)
- Age
- Adult, Older Adult · 60+ yrs
- Sex
- All
- Sponsor
- University of Arkansas
- Primary completion
- Nov 2018
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Whole Body Net Balance Measured by Gas Chromatography-Mass Spectrometry (GC-MS) |
14.58; 14.55 | — |
| SECONDARY Change in Skeletal Muscle Protein Metabolism Measured by Gas Chromatography-Mass Spectrometry (GC-MS) |
0.0043; 0.0081 | 0.05 |
Summary
The specific hypothesis is that the consumption of 2 Hayward green kiwifruit (containing actinidin protease) prior to 100g of ground beef will increase the rate of protein digestion from the beef in the elderly, leading to an increased uptake of the essential amino acids. Furthermore, this increased essential amino acid availability will produce a greater postprandial net anabolic protein response, as well as increased fractional synthetic rates of muscle proteins.
Eligibility Criteria
Inclusion Criteria
- men and women ages 60-85 inclusive.
Exclusion Criteria
- Inability to chew meats or difficulty swallowing solid foods
- History of diabetes
- History of malignancy in the 6 months prior to enrolment
- History of gastrointestinal reduction or bypass surgery (Lapband, etc)
- History of a chronic inflammatory condition or disease (Lupus, HIV'AIDS, etc)
- History of chronic kidney disease or currently requiring dialysis.
- Allergy to beef or kiwifruit
- Subjects who do not or will not eat animal proteins
- Subjects who cannot refrain from consuming protein or amino acid supplements during their participation in this study
- Subjects who report regular resistance exercise (more than once per week)
- Hemoglobin less than 9.5mg/dL at the screening visit
- Platelets less than <150, 000 at the screening visit
- Subjects who are not willing or able to suspend aspirin for several days prior to their muscle biopsies.
- Subjects who have been prescribed a blood-thinning medication (Coumadin, lovenox, heparin, Plavix, etc).
- Concomitant use of corticosteroids (ingestion, injection or transdermal)
- Any other disease or condition that would place the subject at increased risk of harm if they were to participate, at the discretion of the study physician
Data sourced from ClinicalTrials.gov (NCT04356573). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.